RTRX Retrophin Inc

Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results

Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information

Date:Tuesday, February 26, 2019
Time: 4:30 p.m. ET
Dial-in numbers:+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)
Confirmation code:3878749
Live webcast: in the “Events & Presentations” section of the “Investors” page

A replay of the call will be available from 7:30 p.m. ET, February 26, 2019 to 7:30 p.m. ET, March 5, 2019. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 3878749.

About Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.

Contact:

Chris Cline, CFA

Vice President, Investor Relations & Corporate Communications

760-260-8600

EN
12/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by Retrophin Inc

ValuEngine Rating and Forecast Report for RTRX

ValuEngine Rating and Forecast Report for RTRX

ValuEngine Rating and Forecast Report for RTRX

ValuEngine Rating and Forecast Report for RTRX

ValuEngine Rating and Forecast Report for RTRX

ValuEngine Rating and Forecast Report for RTRX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch